脐带血细胞治疗预防COVID-19相关肺炎进展:一项试点随机对照试验的研究方案结构化摘要
本方案描述一项试点性、可行性随机对照试验,旨在评估脐带血来源扩增细胞治疗对SARS-CoV-2感染相关中重度肺炎成年患者的可行性与耐受性,并初步探索其预防进展为重度ARDS的潜在疗效。试验计划在澳大利亚墨尔本Monash医疗中心招募24例住院患者,按1:1随机分配至细胞治疗联合标准支持治疗组或单纯标准支持治疗组,主要评价输注后24小时内的安全性与耐受性及七分类临床改善序贯量表评分。
要点
- 脐带血扩增细胞以5百万细胞/kg(最大500百万细胞)静脉输注,输注时间30-60分钟。
- 主要结局为输注后24小时内安全性与耐受性,以及七分类临床改善序贯量表评分。
- 计划招募24例确诊SARS-CoV-2感染伴肺炎的住院成人患者,1:1随机分组。
核心结论
- 假设扩增脐带血来源细胞治疗对急性COVID-19相关中重度肺炎成年患者可行、耐受良好并具有潜在疗效。
研究设计与样本
- 试点性、平行设计随机对照试验,计划招募24例确诊SARS-CoV-2感染伴肺炎的住院患者。
- 招募地点为澳大利亚墨尔本Monash医疗中心,预计招募时间为2020年7月至12月。
- 随机化采用计算机生成分配,按1:1比例(区组大小为6)使用密封不透光信封进行。
- 研究为非盲设计,不使用安慰剂输注。
关键数值与推荐
- 干预组静脉注射扩增脐带血细胞,剂量为5百万细胞/kg(最大剂量500百万细胞),经外周静脉套管输注30-60分钟。
- 对照组接受标准支持治疗。
- 主要结局包括输注后24小时内的安全性与耐受性,以及七分类临床改善序贯量表评分。
- 每组12例,总样本量n=24。
局限性
- 研究为非盲设计,且不使用安慰剂输注。
- 试验为试点性可行性研究,样本量小(n=24)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Objective: To undertake a pilot, feasibility RCT of umbilical cord blood derived cell therapy for treatment of adult patients infected with SARS-CoV-2 virus related moderate-to-severe pneumonia to prevent progression to severe ARDS. HYPOTHESIS: Expanded cord blood derived cell therapy will be feasible, well tolerated and show potential efficacy in the treatment of acute COVID-19 related moderate to severe pneumonia in adult patients because of their powerful anti-inflammatory and immunomodulatory properties. TRIAL DESIGN: Pilot, parallel design randomised controlled trial. PARTICIPANTS: The trial will recruit 24 hospitalised patients with confirmed SARS-CoV-2 infection and pneumonia from July to December 2020 at Monash Medical Centre in Melbourne, Australia. INTERVENTION AND COMPARATOR: Intervention: Intravenous injection of expanded umbilical cord blood cells at a dose of 5 million cells/kg (maximum dose - 500 million cells). Cell infusion will occur over 30-60 minutes through a peripheral intravenous cannula. Standard supportive care will continue as needed. Comparator: Standard supportive care. MAIN OUTCOMES: Safety and tolerability of cell administration within first 24 hours of administration; clinical improvement on a seven-category clinical improvement ordinal scale. RANDOMISATION: Randomisation will be done using computer generated allocation to intervention/ control groups in a 1:1 ratio (in blocks of 6) using sealed opaque envelopes. BLINDING (MASKING): This will be an unblinded study, given that it is the first study using expanded cord blood cells in COVID-19 patients. There will be no placebo infusion. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): Twelve participants in each group. Total n=24. TRIAL STATUS: CBC-19 protocol v2, dated 23rd April 2020. Recruitment has not started yet. Estimated recruitment timeline is between 1st July - 31st December 2020. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry, ACTRN12620000478910, registered 16th April 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
引用
- Malhotra A, Ernest D, Rogers BA, et al. Umbilical cord blood therapy to prevent progression of COVID-19 related pneumonia: a structured summary of a study protocol for a pilot randomised controlled trial. Trials. 2020. PMID: 32493459. doi:10.1186/s13063-020-04387-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。